​

Contineum Therapeutics (CTNM) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CTNM Stock Forecast

Contineum Therapeutics (CTNM) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $21.33, with a high of $28.00 and a low of $17.00. This represents a 128.62% increase from the last price of $9.33.

$5 $10 $15 $20 $25 $30 High: $28 Avg: $21.33 Low: $17 Last Closed Price: $9.33

CTNM Stock Rating

Contineum Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (50.00%), 2 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 2 2 Strong Sell Sell Hold Buy Strong Buy

CTNM Price Target Upside V Benchmarks

TypeNameUpside
StockContineum Therapeutics128.62%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-37
Avg Price Target-$21.33$18.57
Last Closing Price$9.33$9.33$9.33
Upside/Downside-128.62%99.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26161--8
Sep, 26161--8
Aug, 26161--8
Jul, 26151--7
Jun, 26151--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 30, 2026Paul MatteisStifel Nicolaus$28.00$12.92116.72%200.11%
Sep 27, 2026Sean LaamanMorgan Stanley$17.00$12.5635.35%82.21%
Sep 15, 2026Robert W. Baird$19.00$14.8228.21%103.64%
May 14, 2026Morgan Stanley$16.00$14.1513.07%71.49%
Jan 08, 2026Morgan Stanley$14.00$9.5646.44%50.05%
Nov 24, 2025Robert W. Baird$14.00$10.9527.85%50.05%
Nov 21, 2025Brian AbrahamsRBC Capital$22.00$12.2280.03%135.80%
Sep 25, 2025Leerink Partners$20.00$10.8684.16%114.36%
Mar 07, 2025Robert W. Baird$16.00$6.77136.34%71.49%
Oct 21, 2024Joel BeattyRobert W. Baird$32.00$16.0799.13%242.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 21, 2025RBC CapitalOutperformOutperformhold
Jun 18, 2025William BlairOutperforminitialise
Aug 14, 2024RBC CapitalOutperformOutperformhold
Apr 30, 2024Morgan StanleyOverweightinitialise
Apr 30, 2024RBC CapitalOutperforminitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.90$-2.18$-2.17---
Avg Forecast-$-1.92$-1.81$-3.11$-3.27$-4.88
High Forecast-$-1.82$-1.77$-3.11$-3.27$-4.88
Low Forecast-$-2.00$-1.84$-3.11$-3.27$-4.88
Surprise %-13.54%19.89%---

Revenue Forecast

$5M $14M $23M $32M $41M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.00M-----
Avg Forecast$50.00M$50.00M$7.50M$50.00M$50.00M$50.00M
High Forecast$50.00M$50.00M$7.50M$50.00M$50.00M$50.00M
Low Forecast$50.00M$50.00M$7.50M$50.00M$50.00M$50.00M
Surprise %------

Net Income Forecast

$-100M $-70M $-40M $-10M $20M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$22.72M$-42.26M$-59.98M---
Avg Forecast-$-34.03M$-32.08M$-55.15M$-57.99M$-86.67M
High Forecast-$-32.34M$-31.39M$-55.15M$-57.99M$-86.67M
Low Forecast-$-35.55M$-32.76M$-55.15M$-57.99M$-86.67M
Surprise %-24.18%86.99%---

CTNM Forecast FAQ

Is Contineum Therapeutics stock a buy?

Contineum Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Contineum Therapeutics is a favorable investment for most analysts.

What is Contineum Therapeutics's price target?

Contineum Therapeutics's price target, set by 4 Wall Street analysts, averages $21.33 over the next 12 months. The price target range spans from $17 at the low end to $28 at the high end, suggesting a potential 128.62% change from the previous closing price of $9.33.

How does Contineum Therapeutics stock forecast compare to its benchmarks?

Contineum Therapeutics's stock forecast shows a 128.62% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Contineum Therapeutics over the past three months?

  • October 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Contineum Therapeutics’s EPS forecast?

Contineum Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.11, marking a 43.32% increase from the reported $-2.17 in 2025. Estimates for the following years are $-3.27 in 2027, and $-4.88 in 2028.

What is Contineum Therapeutics’s revenue forecast?

Contineum Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $50M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $50M, and $50M for 2028.

What is Contineum Therapeutics’s net income forecast?

Contineum Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-55.147M, representing a -8.05% decrease from the reported $-59.978M in 2025. Projections indicate $-57.989M in 2027, and $-86.672M in 2028.